|Bid||13.50 x 4000|
|Ask||13.90 x 1200|
|Day's Range||13.73 - 13.86|
|52 Week Range||13.05 - 17.31|
|Beta (5Y Monthly)||1.00|
|PE Ratio (TTM)||10.63|
|Forward Dividend & Yield||0.80 (5.60%)|
|Ex-Dividend Date||Sept 29, 2021|
|1y Target Est||17.76|
CAMBRIDGE, Mass., June 22, 2022--Takeda (TSE:4502/NYSE:TAK) today announced that it has signed a 15-year lease with BioMed Realty for approximately 600,000 square feet of research and development (R&D) and office space to be built at 585 Third Street in Kendall Square. The state-of-the-art facility will allow Takeda, the largest life sciences employer in Massachusetts, to create a purpose-built R&D facility with laboratories of the future featuring modern design elements and upgraded technology
Japan's yen is at its weakest in decades and inflicting high costs of imported food and fuel on households and businesses, but also proving to be an unexpected tailwind for multinationals such as pharmaceutical giant Takeda. As the Bank of Japan reiterated its commitment to loose monetary policy on Friday, affirming its position as a standalone dove in a global environment of rising inflation, the yen edged back towards the 135.60-per-dollar lows it struck this week. Nearly half of companies that responded to a Tokyo Shoko Research poll this week said the weaker yen would have a negative impact on their businesses.
Dividend stocks are just as prone as other stocks to underperforming the market and doing pretty much everything except what you want them to do -- increase and pay out. The catch is that some of the worst dividend investing mistakes are disguised as being juicy opportunities. Let's go over three of the most tempting and most destructive foibles so that you'll be protected against them when you're figuring out which passive income stocks are worth your money.